Table 2 Baseline and follow-up investigations overall and per treatment arm
Mean (SD) / Median [range] / n (%) | All patients (n = 36) | Cinacalcet (n = 15) | Control (n = 21) | Estimated effect (CI) | p-Value | ||
|---|---|---|---|---|---|---|---|
Baseline | 12 months | Baseline | 12 months | ||||
iPTH (pg/mL) | 730 [318 to 1586] | 665 [353 to1586] | 225 [152 to 386] | 806 [318 to 1096] | 294 [145 to 445] | 146 (− 240, 355) | 0.7 |
Calcium (mmol/L) | 2.30 (0.14) | 2.32 (0.16) | 2.34 (0.17) | 2.29 (0.12) | 2.39 (0.24) | 0.08 (−0.3,0.03) | 0.2 |
Phosphate (mmol/L) | 1.91 (0.58) | 1.91 (0.58) | 1.62 (0.56) | 1.91 (0.59) | 1.61 (0.65) | 0.2 (− 0.3,0.7) | 0.5 |
Haemoglobin (g/L) | 124 (15) | 124 (18) | 119 (20) | 124 (14) | 119 (13) | 7.8 (−17, 36) | 0.5 |
CRP | 11 [0,97] | 16 [0 to 97] | 4 [0.6 to 17] | 7 [0.5 to 52] | 5 [1.6 to 7.4] | 5.1 (−13.1, 8) | 0.6 |
Medication | |||||||
 Calcium Binder | 15 (42%) | 7 (47%) | 8 (53%) | 8 (38%) | 7 (35%) |  | 0.3 |
 Non-calcium binder | 30 (83%) | 13 (87%) | 12 (80%) | 17 (81%) | 12 (60%) |  | 0.3 |
 VDRA | 35 (97%) | 15 (100%) | 14 (93%) | 20 (95%) | 20 (91%) |  | 0.4 |
Vascular stiffness & Carotid intima media thickness | |||||||
 cfPWV (m/s) | 8.6 (3) | 7.8 (2) | 8 (2) | 9.2 (3) | 9.5 (2.6) | −0.2 (−1.6,1.2) | 0.8 |
 Augmentation index (%) | 21 [−10,+ 53] | 21 [−5 to + 37] | 21 [10 to 26] | 26 [− 10 to + 53] | 28 [16 to 35] | 6 (−21, 4) | 0.2 |
 Average CIMT (mm) | 0.04 (0.01) | 0.04 (0.01) | 0.03 (0.01) | 0.04 (0.01) | 0.04 (0.01) | −0.004 (− 0.1,0.002) | 0.2 |
Agatston calcification score | |||||||
 Coronary calc score | 204 [0 to 4075] | 96 [0 to 4075] | 106 [18 to 950] | 260 [8 to 3785] | 464 [60 to1480] | 218 (− 502,387) | 0.8 |
 Aortic calc score | 892 [0 to 16,466] | 302 [0 to 13,063] | 480 [60 to 2224] | 2090 [0 to 16,466] | 2665 [895 to 8567] | 393 (− 382,1224) | 0.3 |
 Total calc score | 2174 [0 to 16,635] | 814 [0 to 15,090] | 852 [165 to 5942] | 3401 [7.5 to 16,635] | 4768 [996 to 9582] | 455 (− 564,1293) | 0.4 |
 Cardiac magnetic resonance | (n = 32) | (n = 12) |  | (n = 20) |  |  |  |
 LV mass index (g/m2) | 109 (39) | 120 (43) | 92 (31) | 103 (37) | 90 (20) | −0.2 (−1.2,0.8) | 0.7 |
 LV stroke volume (mL) | 92 (22) | 102 (22) | 103 (24) | 87 (19) | 98 (22) | −0.5 (−16,15) | 0.9 |
 LV ejection fraction (%) | 68 (11) | 70 (7) | 70 (8) | 67 (13) | 70 (10) | −0.5 (−7,6) | 0.9 |
Bone density | (n = 36) | (n = 15) |  | (n = 19) |  |  |  |
 DXA spine BMD g/m2 | 1.1 (0.2) | 1.1 (0.1) | 1.1 (0.1) | 1.1 (0.2) | 1.1 (0.2) | −0.03 (−0.07,0.001) | 0.1 |
 DXA hip BMD | 0.9 (0.1) | 0.9 (0.1) | 0.9 (0.1) | 0.8 (0.2) | 0.8 (0.2) | −0.01 (−0.03,0.2) | 0.4 |
 DXA femoral BMD | 0.8 (0.1) | 0.9 (0.1) | 0.9 (0.1) | 0.8 (0.1) | 0.8 (0.2) | −0.01 (− 0.04,0.02) | 0.6 |
 QCT BMD | 126 (48) | 134 (38) | 136 (38) | 120 (54) | 120 (40) | −2.7 (−14,9.1) | 0.6 |
 pQCT50 cortcnt | 80 (30) | 86 (23) | 90 (21) | 75 (33) | 82 (27) | 5.1 (−2.5,12.8) | 0.2 |
 Stress strain index | 215 (99) | 227 (68) | 244 (66) | 207 (54) | 202 (94) | 28 (−3.8,59.6) | 0.08 |
Biomarkers | |||||||
 NTproBNP (pg/mL) | 2945[332to161680] | 2483[679to80840] | 3066 [90to49520] | 3011[332to161680] | 3208 [107to126250] | 0.01 (−0.4,0.4) | 0.9 |
 Troponin T (ug/L) | 33 [11 to 199] | 27 [11 to 89] | 30 [4 to 1478] | 38 [12 to 198] | 42 [14 to 131] | 0.1 (−0.2,0.4) | 0.5 |
 25(OH) Vitamin D (nmol/L) | 13 [4 to 33] | 16 [6 to 59] | 16 [4 to 34] | 11 [4 to 33] | 13 [4 to 33] | −0.1 (−0.3,0.7) | 0.2 |
 1,25 (OH)2 Vitamin D (pmol/L) | 66 [34 to 132] | 62 [34 to 130] | 65 [50 to 91] | 70 [39 to 132] | 78 [54 to 122] | −0.1 (−0.3,0.8) | 0.3 |
 Osteoprotegerin (pmol/L) | 8 [3 to 23] | 8 [3 to 17] | 8 [3 to 18] | 8 [4 to 23] | 8 [4 to 17] | 0.4 (−0.4,0.1) | 0.3 |
 FGF23 (RU/mL) | 13,794 [412 to 149,994] | 22,243 [774 to 149,994] | 7422 [328 to 117,011] | 13,793 [412 to 60,933] | 11,540 [195 to 143,782] | −0.06 (−0.6,0.5) | 0.8 |
 Fetuin A (ng/mL) | 342 [190 to 588] | 363 [290 to 562] | 369 [154 to 538] | 321 [190 to 588] | 343 [161 to 580] | −0.2 (−0.9,0.6) | 0.7 |